Artificial liver support systems: what is new over the last decade?

Annals of Intensive Care

Table 4 Studies using MARS in clinical indications other than for ALF or AoCLF

Study	Years	Design	Patients number	Clinical indication	Outcomes	LOE
Wong et al. [61]	2009	Uncontrolled, prospective	6	Type 1 HRS refractory to vasoconstrictor therapy	No improvement in haemodynamics	3
					No improvement in GFR; temporary improvement of creatinine during MARS**
					Reduction in NO levels**
Schaefer et al. [62]	2012	Uncontrolled, retrospective	3	Severe cholestatic pruritus	Paediatric patients	3
					Significant decrease in NRS score*
					135 MARS sessions in total, during 4, 8 and 13 months prior liver transplantation
Lavayssière et al. [63]	2013	Uncontrolled, retrospective	32	Type 1 HRS	No improvement in renal function	3
					In patients receiving norepinephrine, significant dose reductions**
Gilg et al. [64]	2018	Uncontrolled, prospective	10	Post-hepatectomy liver failure	No improvement in MELD	3
					No major complications reported

LOE level of evidence, determined using the strength of recommendation taxonomy (SORT) criteria [50], HRS hepatorenal syndrome, GFR glomerular filtration rate, NO nitric oxide, NRS score numeric rating scale, NRS 0: no pruritus, NRS 10: maximal pruritus, MELD model for end-stage liver disease
*p < 0.01
**p < 0.05